Understanding genetic and environmental factors in pulmonary fibrosis
Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland [PRECISE-PF]
This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Royal College of Surgeons, Ireland Academic / other |
| Locations | 1 site (Dublin) |
| Trial ID | NCT06702228 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on improving the understanding of how genetic and environmental factors contribute to pulmonary fibrosis. It aims to identify specific genes and other risk factors that may influence the development and progression of this disease. Participants will undergo various assessments, including genetic testing, CT scans, and quality of life questionnaires, to gather comprehensive data on their condition. The study will involve patients diagnosed with fibrotic interstitial lung diseases, including idiopathic pulmonary fibrosis.
Who should consider this trial
Good fit: Ideal candidates include individuals with a multidisciplinary team diagnosis of fibrotic interstitial lung disease or idiopathic pulmonary fibrosis, as well as those with specific connective tissue diseases.
Not a fit: Patients currently participating in interventional clinical trials or those with acute or chronic hypersensitivity pneumonitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools and personalized care strategies for patients with pulmonary fibrosis.
How similar studies have performed: Other studies have shown promise in understanding genetic influences on pulmonary fibrosis, but this approach may offer novel insights specific to familial cases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able and willing to give written informed consent. * An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories; 1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD 2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis. 3. Meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus. Exclusion Criteria: * Currently participating in an interventional clinic trial. * Change in clinical phenotype from initial radiological diagnosis to screening. * Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins). * Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure) * Life expectancy for any disease, including ILD \<12 months (investigator assessment) * Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)
Where this trial is running
Dublin
- Beaumont Hospital — Dublin, Ireland (Recruiting)
Study contacts
- Principal investigator: Killian Hurley — Rcsi
- Study coordinator: Killian Hurley
- Email: killianhurley@rcsi.ie
- Phone: +35318093000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.